# Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation

> **NCT02630004** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spherium Biomed** · enrollment: 84 (actual)

## Conditions studied

- Oral Mucositis

## Interventions

- **DRUG:** Melatonin oral gel 3%
- **DRUG:** Placebo oral gel

## Key facts

- **NCT ID:** NCT02630004
- **Lead sponsor:** Spherium Biomed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12-22
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630004, "Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02630004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*